Filing Details
- Accession Number:
- 0001209191-20-013020
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-02-26 16:30:31
- Reporting Period:
- 2020-02-24
- Accepted Time:
- 2020-02-26 16:30:31
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1557290 | A Stuart Arbuckle | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Evp, Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2020-02-24 | 2,898 | $239.23 | 38,813 | No | 4 | F | Direct | |
| Common Stock | Disposition | 2020-02-25 | 810 | $229.78 | 38,003 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-25 | 432 | $230.85 | 37,571 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-25 | 360 | $232.35 | 37,211 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-25 | 420 | $234.08 | 36,791 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-25 | 540 | $235.14 | 36,251 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-25 | 420 | $236.36 | 35,831 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-25 | 20 | $236.88 | 35,811 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-02-25 | 632 | $238.33 | 35,179 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | F | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 140 | Indirect | 401(k) |
Footnotes
- Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $229.78 (range $229.21 to $230.14).
- Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $230.85 (range $230.51 to $231.30).
- Open market sales reported on this line occurred at a weighted average price of $232.35 (range $232.03 to $232.72).
- Open market sales reported on this line occurred at a weighted average price of $234.08 (range $233.57 to $234.44).
- Open market sales reported on this line occurred at a weighted average price of $235.14 (range $234.61 to $235.56).
- Open market sales reported on this line occurred at a weighted average price of $236.36 (range $235.69 to $236.65).
- Open market sales reported on this line occurred at a weighted average price of $238.33 (range $237.98 to $238.54).
Billionaire Hedge Funds
